Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Varea

Showing results (491-500 of 506) with videos related to

Pageof 51
Sort By:
Frontiers in Immunology|November 3, 2025
Macrophage activation syndrome-like in multiple myeloma patients treated with the academic CAR-T against BCMA ARI0002hDaniel Munárriz, Luis Gerardo Rodríguez-Lobato, Lucía López-Corral, et al.
British Journal of Haematology|June 4, 2026
Cesni-cel (ARI0002h) in ultra-high-risk multiple myeloma with plasma cell leukaemia or central nervous system involvementCarlos Jimenez-Mira, Natalia Tovar, Núria Martínez-Cibrián, et al.
Viruses|June 2, 2021
Pregnancy Outcomes and SARS-CoV-2 Infection: The Spanish Obstetric Emergency Group StudySara Cruz Melguizo, María Luisa de la Cruz Conty, Paola Carmona Payán, et al.
Blood Advances|November 27, 2024
Clinical impact of [18F]FDG-PET/CT in ARI0002h treatment, a CAR-T against BCMA for relapsed/refractory multiple myelomaInés Zugasti, Marta Tormo-Ratera, Aina Oliver-Caldés, et al.
Environment International|September 23, 2022
Toenail zinc as a biomarker: Relationship with sources of environmental exposure and with genetic variability in MCC-Spain studyEnrique Gutiérrez-González, Pablo Fernández-Navarro, Roberto Pastor-Barriuso, et al.
British Journal of Haematology|October 31, 2023
The academic point-of-care anti-CD19 chimeric antigen receptor T-cell product varnimcabtagene autoleucel (ARI-0001 cells) shows efficacy and safety in the treatment of relapsed/refractory B-cell non-Hodgkin lymphomaNúria Martínez-Cibrián, Valentín Ortiz-Maldonado, Marta Español-Rego, et al.
The Lancet. Oncology|July 6, 2023
Fractionated initial infusion and booster dose of ARI0002h, a humanised, BCMA-directed CAR T-cell therapy, for patients with relapsed or refractory multiple myeloma (CARTBCMA-HCB-01): a single-arm, multicentre, academic pilot studyAina Oliver-Caldés, Verónica González-Calle, Valentín Cabañas, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|October 3, 2020
CART19-BE-01: A Multicenter Trial of ARI-0001 Cell Therapy in Patients with CD19<sup>+</sup> Relapsed/Refractory MalignanciesValentín Ortíz-Maldonado, Susana Rives, Maria Castellà, et al.
Hemasphere|September 15, 2025
Efficacy and safety of the academic anti-CD19 chimeric antigen receptor T-cell product varnimcabtagene autoleucel for the treatment of relapsed/refractory follicular lymphomaNúria Martínez-Cibrián, Valentín Ortiz-Maldonado, Marta Español-Rego, et al.
Biomedicine Hub|February 10, 2021
Bringing Greater Accuracy to Europe's Healthcare Systems: The Unexploited Potential of Biomarker Testing in OncologyDenis Horgan, Gennaro Ciliberto, Pierfranco Conte, et al.
Pageof 51

Showing results (491-500 of 506) with videos related to

Sort By:
Pageof 51
Frontiers in Immunology|November 3, 2025
Macrophage activation syndrome-like in multiple myeloma patients treated with the academic CAR-T against BCMA ARI0002hDaniel Munárriz, Luis Gerardo Rodríguez-Lobato, Lucía López-Corral, et al.
British Journal of Haematology|June 4, 2026
Cesni-cel (ARI0002h) in ultra-high-risk multiple myeloma with plasma cell leukaemia or central nervous system involvementCarlos Jimenez-Mira, Natalia Tovar, Núria Martínez-Cibrián, et al.
Viruses|June 2, 2021
Pregnancy Outcomes and SARS-CoV-2 Infection: The Spanish Obstetric Emergency Group StudySara Cruz Melguizo, María Luisa de la Cruz Conty, Paola Carmona Payán, et al.
Blood Advances|November 27, 2024
Clinical impact of [18F]FDG-PET/CT in ARI0002h treatment, a CAR-T against BCMA for relapsed/refractory multiple myelomaInés Zugasti, Marta Tormo-Ratera, Aina Oliver-Caldés, et al.
Environment International|September 23, 2022
Toenail zinc as a biomarker: Relationship with sources of environmental exposure and with genetic variability in MCC-Spain studyEnrique Gutiérrez-González, Pablo Fernández-Navarro, Roberto Pastor-Barriuso, et al.
British Journal of Haematology|October 31, 2023
The academic point-of-care anti-CD19 chimeric antigen receptor T-cell product varnimcabtagene autoleucel (ARI-0001 cells) shows efficacy and safety in the treatment of relapsed/refractory B-cell non-Hodgkin lymphomaNúria Martínez-Cibrián, Valentín Ortiz-Maldonado, Marta Español-Rego, et al.
The Lancet. Oncology|July 6, 2023
Fractionated initial infusion and booster dose of ARI0002h, a humanised, BCMA-directed CAR T-cell therapy, for patients with relapsed or refractory multiple myeloma (CARTBCMA-HCB-01): a single-arm, multicentre, academic pilot studyAina Oliver-Caldés, Verónica González-Calle, Valentín Cabañas, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|October 3, 2020
CART19-BE-01: A Multicenter Trial of ARI-0001 Cell Therapy in Patients with CD19<sup>+</sup> Relapsed/Refractory MalignanciesValentín Ortíz-Maldonado, Susana Rives, Maria Castellà, et al.
Hemasphere|September 15, 2025
Efficacy and safety of the academic anti-CD19 chimeric antigen receptor T-cell product varnimcabtagene autoleucel for the treatment of relapsed/refractory follicular lymphomaNúria Martínez-Cibrián, Valentín Ortiz-Maldonado, Marta Español-Rego, et al.
Biomedicine Hub|February 10, 2021
Bringing Greater Accuracy to Europe's Healthcare Systems: The Unexploited Potential of Biomarker Testing in OncologyDenis Horgan, Gennaro Ciliberto, Pierfranco Conte, et al.
Pageof 51